
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
BioNTech's COVID-19 vaccine (co-developed with Pfizer) has made headlines with the announcement of its 90% efficacy rate. But this early data is subject to change and the vaccine must pass rigorous testing by the Therapeutic Goods Administration’s (TGA) before it's approved for use in Australia.
BioNTech SE is a biotechnology business with stocks listed in the US. BioNTech shares (BNTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$102.6 – a decrease of -INF% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | US$37 - US$131 |
---|---|
50-day moving average | US$105.3035 |
200-day moving average | US$100.2671 |
Target price | US$125.91 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | US$-0.5631 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of $102.6
1 month (2021-03-12) | -0.66% |
---|---|
3 months (2021-01-12) | -2.70% |
6 months (2020-10-12) | 15.62% |
1 year (2020-04-09) | 125.94% |
---|
Revenue TTM | US$567.6 million |
---|---|
Gross profit TTM | US$-222,037,000 |
Return on assets TTM | -13.07% |
Return on equity TTM | 1.63% |
Profit margin | 3.15% |
Book value | N/A |
Market capitalisation | US$27.4 billion |
TTM: trailing 12 months
There are currently 3.8 million BioNTech shares held short by investors – that's known as BioNTech's "short interest". This figure is 4.9% up from 3.6 million last month.
There are a few different ways that this level of interest in shorting BioNTech shares can be evaluated.
BioNTech's "short interest ratio" (SIR) is the quantity of BioNTech shares currently shorted divided by the average quantity of BioNTech shares traded daily (recently around 1.4 million). BioNTech's SIR currently stands at 2.66. In other words for every 100,000 BioNTech shares traded daily on the market, roughly 2660 shares are currently held short.
However BioNTech's short interest can also be evaluated against the total number of BioNTech shares, or, against the total number of tradable BioNTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioNTech's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 BioNTech shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable BioNTech shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioNTech.
Find out more about how you can short BioNTech stock.
We're not expecting BioNTech to pay a dividend over the next 12 months.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Steps to owning and managing Zebit shares.
Steps to owning and managing CleanSpace shares.
Steps to owning and managing Benz Mining shares.
Steps to owning and managing Top Shelf International shares.
Steps to owning and managing K12 Inc shares from Australia.
Steps to owning and managing 2U Inc shares from Australia.
Steps to owning and managing Chegg Inc shares from Australia.
Steps to owning and managing Liberty Financial Group shares.
Steps to owning and managing Cettire shares.
Steps to owning and managing BHP Group shares.